PeptideOS

Half-life studio

A dose is only half the question. How often you take it decides whether levels hold steady, swing wildly, or clear entirely between injections. Only compounds with a half-life traceable to a real source appear here.

Concentration over timerelative to one dose · 6 doses shown
1.6x0time → 7.0 weeks total
Accumulation
2.00x
peak vs a single dose
Peak / trough
2.0x
swing between doses
To steady state
3.3 weeks
90% of plateau
Loading dose
2.00x
to skip the ramp
Steady profile

Levels build to 2.00x a single dose and swing 2.0x between peak and trough, a relatively steady profile for this half-life.

Half-life source and model assumptions

Half-life used: 7.0 days · human data · subcutaneous

Approximately 1 week. Long half-life is driven by albumin binding, which slows renal clearance and protects against DPP-4 degradation. Present in circulation for ~5 weeks after the last dose.

This is a one-compartment model with first-order elimination, shown in multiples of a single dose rather than absolute blood levels, the volume of distribution is unknown for most of these compounds, so any absolute concentration would be invented. Ratios, accumulation, and time-to-plateau do not depend on it. Real pharmacokinetics vary between people; this describes the shape of a curve, not what will happen in your body.